Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3817 - First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry


11 Sep 2017


Poster display session


Breast Cancer


Mohammad Jahanzeb


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


M. Jahanzeb1, D. Tripathy2, S.A. Hurvitz3, J. O'Shaughnessy4, G. Mason5, D.A. Yardley6, A. Brufsky7, H.S. Rugo8, M. Cobleigh9, S.M. Swain10, L. Chu11, V. Antao12, B. Yoo13, P.A. Kaufman14

Author affiliations

  • 1 Sylvester Comprehensive Cancer Center, University of Miami, FL 33442 - Deerfield Beach/US
  • 2 Md Anderson Cancer Center, University of Texas, Houston/US
  • 3 Jonsson Comprehensive Cancer Center And Translational Research In Oncology, University of California Los Angeles, Los Angeles/US
  • 4 Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas/US
  • 5 Board Of Directors, Inflammatory Breast Cancer Research Foundation, West Lafayette/US
  • 6 Breast Cancer Research Program, Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville/US
  • 7 Cancer Institute, University of Pittsburgh, Pittsburgh/US
  • 8 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco/US
  • 9 Department Of Internal Medicine, Rush University Medical Center, Chicago/US
  • 10 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington/US
  • 11 Biooncology, Genentech, Inc., 80 - South San Francisco/US
  • 12 Biooncology, Genentech, Inc., South San Francisco/US
  • 13 Biostatistics, Genentech, Inc., South San Francisco/US
  • 14 Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, 3756 - Lebanon/US


Abstract 3817


Clinical outcomes for pts with HER2+ MBC may differ by age, potentially influenced by differences in treatment regimens administered to older vs younger pts. Systematic Therapies for HER2+ Metastatic Breast Cancer Study (SystHERs) captures real-world treatment patterns and outcomes in pts with HER2+ MBC. Here, we examine baseline characteristics, first-line treatments, and breast cancer–specific survival (BCSS) by age.


SystHERs is a fully enrolled (Jun 2012–Jun 2016), ongoing, US-based, observational study. Pts were ≥18 years old and had HER2+ MBC diagnosed within 6 months of enrollment. Pts were grouped by age at MBC diagnosis (


As of Feb 10, 2017, of 978 eligible pts, 287 were


In this preliminary real-world analysis of pts with HER2+ MBC, pertuzumab (P) + trastuzumab (H) was more commonly used than H without P across all age groups. Pts

Clinical trial identification


Legal entity responsible for the study





M. Jahanzeb: Consulting fees from Roche. Data and Safety Monitoring Board for Puma. D. Tripathy: Consulting fees from Puma Biotech, NEKTAR Pharma, Novartis. Contracted research paid to institution from Novartis. S.A. Hurvitz: Research funding from Amgen, Bayer, Boehringer Ingleheim, Genentech, GSK, Pfizer, Roche, Biomarin, Merrimack, PUMA, Dignitana, Medication. Research and travel from Lilly, Novartis, OBI Pharma. J. O\'Shaughnessy: Consulting fees from Genentech. G. Mason: Advisory Board: Avon Foundation for Women Scientific. D.A. Yardley: Fees for services from Novartis and Genentech. Contracted research paid to institution from Genentech and Novartis. A. Brufsky: Consulting fees from Roche. H.S. Rugo: Fees for services from Genomic Health. contracted research paid to institution from Genentech, Pfizer, Novartis, Lilly, OBI Pharma, GTX, Macrogenics, Merck. M. Cobleigh: Royalties and Receipt of IP rights from Genomic Health. Consulting fees from Genentech/Roche and GSK. Contracted research from Genentech/Roche, Merrimack, Macrogenics, NRG foundation. S.M. Swain: Consulting fees from Genentech/Roche, Novartis, and Pieris. Contracted research paid to institution from Genentech/Roche, Pfizer, Merrimack, and Lilly. L. Chu, V. Antao, B. Yoo: Employment at Genentech. Stock ownership in Roche. P.A. Kaufman: Consulting fees from Genentech. Contracted research paid to institution from Genentech/Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.